Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Market Closed 01-16 16:00:00 EST

733.04

-8.88

-1.20%

盘后733.04

+0.000.00%

19:40 EST

High749.09	Low726.43	Vol1.68M
Open749.09	D1 Closing741.92	Amplitude3.05%
Mkt Cap77.04B	Tradable Cap75.73B	Total Shares105.10M
T/O1.23B	T/O Rate1.63%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":733.04,"timestamp":1768597200000,"preClose":741.92,"halted":0,"volume":1682566,"hourTrading":{"tag":"盘后","latestPrice":733.04,"preClose":733.04,"latestTime":"19:40 EST","volume":468741,"amount":343611002.32322,"timestamp":1768610431146},"delay":0,"floatShares":103302739,"shares":105099464,"eps":41.59414,"marketStatus":"Market Closed","change":-8.88,"latestTime":"01-16 16:00:00 EST","open":749.09,"high":749.09,"low":726.43,"amount":1234100646.38704,"amplitude":0.030542,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":741.92,"dividendRate":0.004802,"preHourTrading":{"tag":"盘前","latestPrice":744.28,"preClose":741.92,"latestTime":"09:29 EST","volume":14483,"amount":10745341.775700001,"timestamp":1768573774679},"postHourTrading":{"tag":"盘后","latestPrice":733.04,"preClose":733.04,"latestTime":"19:40 EST","volume":468741,"amount":343611002.32322,"timestamp":1768610431146},"volumeRatio":1.8635884050891534,"impliedVol":0.381,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2604911522","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2604911522","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604911522?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:41","pubTimestamp":1768599660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slipped 1.20% to $733.04 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.06% to 6,940.01 and Dow Jones Industrial Average  falling 0.17% to 49,359.33.This was the stock's seventh consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 10.73% below its 52-week high of $821.11, which the company achieved on January 9th.The stock underperformed when compared to some of its competitors Friday, as Amgen Inc.  rose 0.12% to $330.41, Moderna Inc.  rose 6.28% to $41.83, and Gilead Sciences Inc.  rose 3.01% to $124.91.Trading volume  eclipsed its 50-day average volume of 978,207.Data source: Dow Jones Market Data, FactSet. Data compiled January 16, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2603993385","title":"EU Approves Bayer’s Eylea 8 mg for Macular Edema Following Retinal Vein Occlusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2603993385","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603993385?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:06","pubTimestamp":1768565182,"startTime":"0","endTime":"0","summary":"Bayer AG has received marketing authorization from the European Commission for Eylea 8 mg  in the European Union for the treatment of patients with visual impairment due to macular edema following retinal vein occlusion , including branch, central, and hemiretinal vein occlusion. This approval marks the third retinal indication for Eylea 8 mg in the EU, where it is already approved for neovascular  age-related macular degeneration  and diabetic macular edema . Eylea 8 mg is the first and only anti-VEGF treatment approved for extended treatment intervals of up to six months in both nAMD and DME in the EU and UK. The product is jointly developed by Bayer and Regeneron, with Bayer holding exclusive marketing rights outside the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLZMxSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","BK4585","LU2362541273.HKD","BK4588","LU0109394709.USD","BK4139","LU0823434583.USD","LU0823434740.USD","LU0114720955.EUR","LU0289739699.SGD","LU2237438978.USD","LU0053666078.USD","LU2468319806.SGD","LU2106854487.HKD","LU0058720904.USD","LU0823416689.USD","LU2023250504.SGD","LU0320765992.SGD","LU0882574055.USD","LU2089984988.USD","LU2362541513.USD","LU2362540622.SGD","LU1974910355.USD","LU0889565916.HKD","LU1917777945.USD"],"gpt_icon":0},{"id":"2603933323","title":"Analysts’ Top Healthcare Picks: Regeneron (REGN), Ocugen (OCGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603933323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603933323?lang=en_us&edition=fundamental","pubTime":"2026-01-16 03:50","pubTimestamp":1768506636,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Ocugen (OCGN ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-regeneron-regn-ocugen-ocgn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-regeneron-regn-ocugen-ocgn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0058720904.USD","LU0109394709.USD","OCGN","BK4137","LU0053666078.USD","LU1974910355.USD","LU2023250504.SGD","LU0128526141.USD","LU2106854487.HKD","LU0823416689.USD","LU0114720955.EUR","BK4585","LU0823434583.USD","LU0882574055.USD","LU2362541513.USD","LU2089984988.USD","BK4568","BK4581","LU2237438978.USD","REGN","LU0889565916.HKD","LU1917777945.USD","LU0289739699.SGD","XBI","XLV","BK4563","HCSG","LU0029874061.USD","BK4139","LU2468319806.SGD","BK4588","LU0823434740.USD","LU2362541273.HKD","LABU","LU2362540622.SGD"],"gpt_icon":0},{"id":"2603646966","title":"CytomX Therapeutics unveils advances in masked oncology therapeutics and pipeline progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2603646966","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603646966?lang=en_us&edition=fundamental","pubTime":"2026-01-15 02:12","pubTimestamp":1768414332,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics Inc. presented updates on its oncology pipeline at the 44th Annual JP Morgan Healthcare Conference. The company highlighted its PROBODY platform, which focuses on masked therapeutics for targeted cancer treatment. Lead clinical programs include varsetatug masetecan , an EpCAM-directed antibody drug conjugate in Phase 1 trials for colorectal cancer, and CX-801  for melanoma. Additional studies are planned, including combination therapies and expansion into other EpCAM-positive indications. CytomX also reported collaborations with Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna, and noted a cash runway into the second quarter of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDLbGgNQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2417539215.USD","IE00B775SV38.USD","LU1548497426.USD","LU1551013425.SGD","IE00BYXW3230.USD","CTMX","REGN","LU2237438978.USD","LU1366192091.USD","AMGN","LU0417517546.SGD","BMY","IE00BJJMRZ35.SGD","LU0256863811.USD","SG9999001440.SGD","LU2264538146.SGD","IE0009355771.USD","LU0985481810.HKD","LU1084165304.USD","LU2054465674.USD","LU0321505868.SGD","LU1988902786.USD","LU1670710661.SGD","LU0070302665.USD","LU2211815571.USD","IE0034235295.USD","LU1914381329.SGD","LU0289739699.SGD","LU0345769631.USD","LU0109394709.USD","LU0203345920.USD","IE0034235188.USD","LU0323591593.USD","LU0942090050.USD","LU2746668974.SGD","LU2462157665.USD","LU0321505439.SGD","LU2430703178.SGD","LU1868836914.USD","LU2237443549.SGD","LU0048584097.USD","LU2242652126.USD","LU1670711040.USD","LU0106261372.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU0820561818.USD","IE00B2B36J28.USD"],"gpt_icon":1},{"id":"2603561193","title":"Jefferies Reaffirms Their Buy Rating on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603561193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603561193?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:57","pubTimestamp":1768399035,"startTime":"0","endTime":"0","summary":"In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Regeneron, with a price target of $885.00. Tewari covers the Hea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2603616099","title":"Regeneron (REGN) Receives a Hold from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616099","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616099?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:18","pubTimestamp":1768396728,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron today and set a price target of $770.00. Chen covers the Healthcare sector, fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/regeneron-regn-receives-a-hold-from-scotiabank-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/regeneron-regn-receives-a-hold-from-scotiabank-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2023250504.SGD","LU1974910355.USD","LU0823434740.USD","BK4581","BK4585","LU1917777945.USD","LU0289739699.SGD","LU0114720955.EUR","LU0058720904.USD","XBI","LABU","REGN","LU0823416689.USD","BK4139","XLV","LU2089984988.USD","LU2106854487.HKD","LU2468319806.SGD","LU0882574055.USD","LU2362540622.SGD","LU2362541273.HKD","LU0053666078.USD","LU0109394709.USD","LU2237438978.USD","LU0320765992.SGD","LU0823434583.USD","BK4588","LU0889565916.HKD","LU2362541513.USD"],"gpt_icon":0},{"id":"2603469359","title":"Leerink Partners Remains a Buy on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603469359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603469359?lang=en_us&edition=fundamental","pubTime":"2026-01-14 15:46","pubTimestamp":1768376768,"startTime":"0","endTime":"0","summary":"In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Regeneron. The company’s shares closed yesterday at...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-remains-a-buy-on-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-remains-a-buy-on-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823434740.USD","LU0053666078.USD","LU2237438978.USD","LU2468319806.SGD","BK4585","LU2362541273.HKD","LU2362540622.SGD","BK4139","LU0823416689.USD","LU2089984988.USD","LU2106854487.HKD","LU0889565916.HKD","LU0109394709.USD","LU0114720955.EUR","LU0823434583.USD","LU2362541513.USD","REGN","BK4588","LU0882574055.USD","LU2023250504.SGD","LU0320765992.SGD","LU1974910355.USD","LU0289739699.SGD","LU1917777945.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2603653830","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653830","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603653830?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:41","pubTimestamp":1768340460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slid 1.18% to $758.91 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.19% to 6,963.74 and Dow Jones Industrial Average  falling 0.80% to 49,191.99.This was the stock's fourth consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 7.58% below its 52-week high of $821.11, which the company reached on January 9th.The stock underperformed when compared to some of its competitors Tuesday, as Amgen Inc.  fell 0.38% to $324.30, Moderna Inc.  rose 17.02% to $39.60, and Gilead Sciences Inc.  fell 0.69% to $121.76.Trading volume  remained 36,772 below its 50-day average volume of 983,162.Data source: Dow Jones Market Data, FactSet. Data compiled January 13, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2603461685","title":"Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603461685","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603461685?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:45","pubTimestamp":1768304751,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $834.12, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2603505575","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603505575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603505575?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:00","pubTimestamp":1768269630,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report), Alkermes (ALKS – Research Rep...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-alkermes-alks-and-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-alkermes-alks-and-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2023250504.SGD","LU0320765992.SGD","LU0053666078.USD","LU2106854487.HKD","APLS","LU1917777945.USD","BK4137","LU0109394709.USD","LU0889565916.HKD","REGN","LU0882574055.USD","LU0823434740.USD","LU1093756325.SGD","LU0128526141.USD","LU2089984988.USD","BK4581","ALKS","LU0029874061.USD","LU0114720955.EUR","LU2362541273.HKD","LU2362541513.USD","BK4585","LU0289739699.SGD","BK4505","LU1974910355.USD","LU1093756168.USD","XBI","LABU","LU2237438978.USD","LU0823416689.USD","BK4139","BK4588","LU0058720904.USD","LU2362540622.SGD","LU0823434583.USD","HCSG","XLV","LU2468319806.SGD"],"gpt_icon":0},{"id":"2603529833","title":"Regeneron Pharmaceuticals Inc. Stock Falls 3.6%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2603529833","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603529833?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:35","pubTimestamp":1768253700,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc. slid 3.6% to $768.00 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.2% to 6,977.27 and the Dow Jones Industrial Average rising 0.2% to 49,590.20.This was the stock's third consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 6.5% short of its 52-week high of $821.11, which the company achieved on January 9th.The stock underperformed when compared to some of its peers, as Amgen Inc. fell 0.2% to $325.54, Moderna Inc. fell 1.3% to $33.84, and Gilead Sciences Inc. rose 1.24% to $122.60.Trading volume totaled 1.3 million, compared to the 50-day average of 991,766.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2602511754","title":"Regeneron Pharmaceuticals Inc - Ipr&D Charge to Negatively Impact Q4 2025 Adj EPS by $0.14 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511754?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:50","pubTimestamp":1768218602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2362541273.HKD","LU0289739699.SGD","LU2362541513.USD","LU2106854487.HKD","BK4585","BK4588","LU0889565916.HKD","LU0823434740.USD","LU0114720955.EUR","LU2362540622.SGD","LU0823416689.USD","LU0882574055.USD","LU0058720904.USD","BK4139","LU1974910355.USD","LU0053666078.USD","LU1917777945.USD","LU2089984988.USD","LU0320765992.SGD","REGN","LU2468319806.SGD","LU0109394709.USD","LU0823434583.USD","LU2237438978.USD","LU2023250504.SGD"],"gpt_icon":0},{"id":"2602313112","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2602313112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602313112?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:41","pubTimestamp":1767908460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slipped 1.39% to $801.01 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.01% to 6,921.46 and the Dow Jones Industrial Average  rising 0.55% to 49,266.11.The stock's fall snapped a two-day winning streak.Regeneron Pharmaceuticals Inc. closed 1.61% below its 52-week high of $814.10, which the company achieved on January 7th.Despite its losses, the stock outperformed some of its competitors Thursday, as Amgen Inc.  fell 3.37% to $330.11, Moderna Inc.  fell 5.66% to $33.86, and Gilead Sciences Inc.  fell 2.96% to $120.67.Trading volume  eclipsed its 50-day average volume of 1.0 M.Data source: Dow Jones Market Data, FactSet. Data compiled January 8, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2602399385","title":"Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $914 From $807, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602399385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602399385?lang=en_us&edition=fundamental","pubTime":"2026-01-09 00:43","pubTimestamp":1767890585,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $828.79, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2601697243","title":"Anavex Life Sciences Appoints Wolfgang Liedtke as Senior Vice President, Global Head of Neurology","url":"https://stock-news.laohu8.com/highlight/detail?id=2601697243","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601697243?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875422,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp. has appointed Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke brings over 25 years of experience in neurology and previously served as Chair of Neurology at Regeneron and as a tenured professor at Duke University.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL67mxPv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU1917777945.USD","LU0823434740.USD","LU0320765992.SGD","LU0889565916.HKD","BK4139","LU0823434583.USD","LU2210150020.SGD","LU1974910355.USD","LU0053666078.USD","LU2095319765.USD","LU0314104364.USD","LU2237438978.USD","BK4585","LU2362541513.USD","LU2089984988.USD","LU0114720955.EUR","AVXL","NDAQ","IE00BKPKM429.USD","LU2468319806.SGD","LU0289739699.SGD","IE00B3QW5Z07.USD","LU2106854487.HKD","LU2210149790.SGD","LU0058720904.USD","LU0109394709.USD","LU0823416689.USD","LU0882574055.USD","BK4588","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2023250504.SGD","IE00B64PRP62.GBP","LU2362540622.SGD","SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2601381380","title":"Regeneron Pharmaceuticals Inc. Stock Advances 4.6%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601381380","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601381380?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:35","pubTimestamp":1767821700,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc. rose 4.6% to $812.27 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.3% to 6,920.93 and Dow Jones Industrial Average falling 0.9% to 48,996.08.This was the stock's second consecutive day of gains.Regeneron Pharmaceuticals Inc. hit a new 52-week high, surpassing its previous peak of $792.77, which the company achieved on December 24th.The stock outperformed some of its peers, as Amgen Inc. rose 3.5% to $341.64, Moderna Inc. rose 0.6% to $35.89, and Gilead Sciences Inc. rose 2.46% to $124.35.Trading volume totaled 1.3 million, compared to the 50-day average of 1.0 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2601593381","title":"Regeneron Just Moved From Underperform To Buy - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2601593381","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601593381?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:18","pubTimestamp":1767820680,"startTime":"0","endTime":"0","summary":"Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/07/Regeneron.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/07/Regeneron.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/26/01/49769970/regeneron-just-moved-from-underperform-to-buy-heres-why","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/26/01/49769970/regeneron-just-moved-from-underperform-to-buy-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0823416689.USD","BK4007","LU0823434740.USD","LU2089984988.USD","LU1917777945.USD","LU0289739699.SGD","BK4588","LU0823434583.USD","LU0109394709.USD","LU0053666078.USD","LU0058720904.USD","LU1974910355.USD","LU2362541513.USD","REGN","LU2237438978.USD","LU0889565916.HKD","LU2106854487.HKD","LU0882574055.USD","LU2023250504.SGD","BK4139","LU2362540622.SGD","BK4585","LU2468319806.SGD","IE00BFXG1179.USD","LU0114720955.EUR","LU2362541273.HKD","SNY","LU0320765992.SGD"],"gpt_icon":0},{"id":"2601138936","title":"Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2601138936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601138936?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:05","pubTimestamp":1767819900,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals stock has trailed behind the broader market over the past year, but there may be a cure for its malaise.The drugmaker has posted an 11% gain in a 12-month period. Not too shabby, but worse than the S&P 500 as well as the S&P 500 Health Care Sector Index, which gained 17% and 14%, respectively.So why take a chance on an underperformer?BofA Securities has an answer to that. The firm upgraded shares of the drugmaker to Buy from Underperform on Wednesday and raised its price target on the stock to $860 from $627.Regeneron was up 4.7% at $813.38. If the gains hold, the stock will notch its highest close since Nov. 12, 2024, when it ended the session at $821, according to Dow Jones Market Data.\"The eyes still have it,\" BofA Securities quipped in a research note. No, seriously: Analysts with the firm see potential in Eylea HD, Regeneron's long-acting eye injection.MFN pricing refers to a policy where drug prices are aligned with the lowest prices paid for the same dr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561909.HKD","LU1571399168.USD","LU0868494617.USD","BK4504","LU1983299246.USD","LU2362541273.HKD","LU0203345920.USD","IE0002141913.USD","LU0321505868.SGD","LU0310800965.SGD","LU1093756325.SGD","LU0203347892.USD","LU0889565916.HKD","LU0320765646.SGD","LU1061106388.HKD","LU1974910355.USD","IE00BBT3K403.USD","SH","BK4207","LU0321505439.SGD","LU0320765489.SGD","LU0256863811.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","LU1718418525.SGD","LU2361044949.HKD","LU0787776722.HKD","BK4553","LU0823411888.USD","LU2112291526.USD","LU1280957306.USD","LU0823434583.USD","SDS","BK4559","IE00B19Z3B42.SGD","LU0823434740.USD","IE00BLSP4239.USD","LU1880398471.USD","ESmain","IE0009355771.USD","LU0306807586.USD","LU1236620834.HKD","LU0648001328.SGD","LU1778281490.HKD","LU1069344957.HKD","BK4550","IE00B19Z3581.USD","IVV","SSO","LU2265009873.SGD","SG9999001440.SGD","LU0354030511.USD","LU1894683264.USD","BK4567","BK4533","IE00BSNM7G36.USD","OEF","LU2362540622.SGD","LU2242652126.USD","IE0034235188.USD","LU1162221912.USD","LU0130517989.USD","LU2237438978.USD","UPRO","BK4588","LU1883839398.USD","LU0820561818.USD","LU1804176565.USD","BK4581","SPXU","LU0640476718.USD","BK4599","IE00BJJMRZ35.SGD","LU1093756168.USD","LU0106831901.USD","LU0052756011.USD","LU1035775433.USD","LU0882574055.USD","LU1880398554.USD","LU2362541513.USD","LU1201861165.SGD","IE0001KFT4U8.USD","BK4585","MESmain","LU0306806265.USD","LU0314106906.USD","LU2756315664.SGD","LU1551013425.SGD","IE00BKVL7J92.USD","LU0208291251.USD","LU0130103400.USD","LU0689472784.USD","LU2023250504.SGD","LU1035773651.USD","HD","LU1674673428.USD","LU1791807156.HKD","LU2129689514.USD","LU2133065610.SGD","LU0683600562.USD","LU0109394709.USD","LU2756315318.SGD","IE00BLSP4452.SGD","LU0098860793.USD","LU1668664300.SGD","LU0942090050.USD","LU0053666078.USD","LU0477156953.USD","BK4139","REGN","LU0289739699.SGD","LU0114720955.EUR","BK4083","LU0058720904.USD","BK4534","LU0130518102.USD","IE00BJT1NW94.SGD","LU0820562030.AUD","LU1057294990.SGD","LU1366192091.USD","LU2129689431.USD","LU2129689605.HKD","LU1267930227.SGD","LU0122379950.USD","LU0149725797.USD","LU0256863902.USD","LU2361044865.SGD","LU0868494708.USD","IE00BFXG1179.USD","LU0070302665.USD","LU0238689110.USD","IE00BWXC8680.SGD","LU1363072403.SGD","LU0823416689.USD","LU0234572021.USD","LU0354030438.USD","LU1074936037.SGD","LU2361045086.USD","LU2468319806.SGD","LU0320765992.SGD","LU1929549753.HKD","LU1023059063.AUD","LU1201861249.SGD","LU1496350502.SGD","LU2461242641.AUD","LU0130102774.USD","LU1894683348.USD","IE0002270589.USD","LU1506573853.SGD","LU0648000940.SGD","LU1989772840.SGD","IE00B1XK9C88.USD","LU1989772923.USD","LU0079474960.USD","LU0971096721.USD","IE00B1BXHZ80.USD","LU1069347547.HKD","LU0128525689.USD","LU1674673691.USD","LU1236620750.USD","IE00B2B36J28.USD","LU1917777945.USD","LU2242646821.SGD","BK4007","IE00B7SZLL34.SGD","IE00B4R5TH58.HKD","LU0943347566.SGD","LU0477156797.USD","IE00BZ1G4Q59.USD","LU1551013342.USD","LU0980610538.SGD","LU2106854487.HKD","OEX","LU1496350171.SGD","LU0170899867.USD","BK4566","LU2089984988.USD","LU1914381329.SGD"],"gpt_icon":0},{"id":"2601802290","title":"BofA Securities Upgrades Regeneron Pharmaceuticals to Buy From Underperform, Raises Price Target to $860 From $627","url":"https://stock-news.laohu8.com/highlight/detail?id=2601802290","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601802290?lang=en_us&edition=fundamental","pubTime":"2026-01-08 00:03","pubTimestamp":1767801783,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $821, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN"],"gpt_icon":0},{"id":"2601029048","title":"Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2601029048","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601029048?lang=en_us&edition=fundamental","pubTime":"2026-01-07 23:54","pubTimestamp":1767801268,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval by the US Food and Drug Administration for the treatment of retinal vein occlusion, BofA Securities","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU0823416689.USD","LU0053666078.USD","LU0823434583.USD","LU0889565916.HKD","LU2023250504.SGD","BK4139","LU1974910355.USD","LU0114720955.EUR","LU2362541273.HKD","LU2106854487.HKD","LU0823434740.USD","LU2362541513.USD","LU2089984988.USD","LU1917777945.USD","REGN","LU2468319806.SGD","LU0320765992.SGD","LU0882574055.USD","LU2237438978.USD","BK4588","LU2362540622.SGD","LU0058720904.USD","BK4585","LU0289739699.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0797},{"period":"1month","weight":-0.0223},{"period":"3month","weight":0.2681},{"period":"6month","weight":0.3512},{"period":"1year","weight":0.0574},{"period":"ytd","weight":-0.0503}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.036439},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction